Abstract: An onboard power supply device includes capacitors, a holder holding the capacitors, a mounting board having the capacitors mounted thereon and having the holder fixed thereto, and a heat-generating component mounted on the mounting board. Each of the capacitors includes a capacitor body and a lead terminal extending from the capacitor body. The holder includes a base part, first holding parts bundled by the base part and holding the capacitors, second holding parts each connected to a corresponding one of the first holding parts, and a fixing part extending from an outer edge of the base part toward the mounting board and fixed to the mounting board. The capacitor body of each of the capacitors is held by a corresponding one of the first holding parts. The lead terminal of each of the capacitors is held by a corresponding one of the second holding parts. The mounting board has a through-hole therein through which the lead terminal passes. The through-hole is connected to the lead terminal.

Abstract: An onboard power supply device includes capacitors, a holder holding the capacitors, a mounting board having the capacitors mounted thereon and having the holder fixed thereto, and a heat-generating component mounted on the mounting board. Each of the capacitors includes a capacitor body and a lead terminal extending from the capacitor body. The holder includes a base part, first holding parts bundled by the base part and holding the capacitors, second holding parts each connected to a corresponding one of the first holding parts, and a fixing part extending from an outer edge of the base part toward the mounting board and fixed to the mounting board. The capacitor body of each of the capacitors is held by a corresponding one of the first holding parts. The lead terminal of each of the capacitors is held by a corresponding one of the second holding parts. The mounting board has a through-hole therein through which the lead terminal passes. The through-hole is connected to the lead terminal.

Abstract: The present invention relates to: an antibody, particularly a monoclonal antibody, a chimeric antibody, a humanized antibody and a human antibody, which specifically recognize human ?9 integrin; a hybridoma cell which produces the monoclonal antibody; a method for producing the monoclonal antibody; a method for producing the hybridoma cell; a therapeutic agent comprising the anti-human ?9 integrin antibody; a diagnostic agent comprising the human ?9 integrin antibody; and a method for screening a compound which inhibits the activity of human ?9 integrin.

Abstract: The present invention relates to: an antibody (particularly a monoclonal antibody), a chimeric antibody, a humanized antibody and a human antibody, which specifically recognize human ?9 integrin; a hybridoma cell which produces the monoclonal antibody; a method for producing the monoclonal antibody; a method for producing the hybridoma cell; a therapeutic agent comprising the anti-human ?9 integrin antibody; a diagnostic agent comprising the human ?9 integrin antibody; a method for screening a compound which inhibits the activity of human ?9 integrin; and the like.

Abstract: The present invention provides an anti-mouse ?9 integrin antibody, an anti-human ?9 integrin antibody, a hybridoma producing any of the antibodies, a method of producing any of the antibodies and the hybridoma, and a pharmaceutical composition comprising any of the antibodies. The anti-?9 integrin antibody of the present invention inhibits the ?9 integrin function thereby to exhibit therapeutic effects on cancer, e.g., the growth and metastasis of a cancer cell, and an inflammatory disease, e.g., rheumatoid arthritis, osteoarthritis, hepatitis, bronchial asthma, fibrosis, diabetes, arteriosclerosis, multiple sclerosis, granuloma, an inflammatory bowel disease (ulcerative colitis and Crohn's disease), an autoimmune disease and the like.

Abstract: The present invention provides an anti-mouse ?9 integrin antibody, an anti-human ?9 integrin antibody, a hybridoma producing any of the antibodies, a method of producing any of the antibodies and the hybridoma, and a pharmaceutical composition comprising any of the antibodies. The anti-?9 integrin antibody of the present invention inhibits the ?9 integrin function thereby to exhibit therapeutic effects on cancer, e.g., the growth and metastasis of a cancer cell, and an inflammatory disease, e.g., rheumatoid arthritis, osteoarthritis, hepatitis, bronchial asthma, fibrosis, diabetes, arteriosclerosis, multiple sclerosis, granuloma, an inflammatory bowel disease (ulcerative colitis and Crohn's disease), an autoimmune disease and the like.